SCHEMBL8060047

SCHEMBL8060047

[CH2]C(C)(NP(=O)(O)Cc1ccccc1)c1c[nH]c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
GABRA4 P48169 1/20 0.38
GABRE P78334 1/20 0.38
GABRA6 Q16445 1/20 0.38
GABRG1 Q8N1C3 1/20 0.38
GABRG3 Q99928 1/20 0.38
GABRQ Q9UN88 1/20 0.38
CFTR P13569 2/20 0.38
SLC6A2 P23975 1/20 0.38
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7612089 0.86 GABRP (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5057877 0.81 ADAM17 (0.40) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7604497 0.81 GABRP (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8423479 0.79 ACP3 (0.42) KDM4EALDH1A1CYP3A4HSD17B10
SCHEMBL7604705 0.79 GABRP (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8426026 0.79 SLC6A2 (0.38) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7609416 0.75 SLC6A2 (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7604593 0.74 DHPS (0.40) CFTR
SCHEMBL7609953 0.73 SLC6A2 (0.40) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7603971 0.72 SLC6A2 (0.39) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP disclosed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO disclosed